## Supplementary Table 4. Dynamics of serum HBsAg levels at week 96

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **HBeAg-positive patients** | | **HBeAg-negative patients** | |
| **TMF 25 mg** | **TDF 300 mg** | **TMF 25 mg** | **TDF 300 mg** |
| **(*n* = 486)** | **(*n* = 246)** | **(*n* = 180)** | **(*n* = 90)** |
| Mean HBsAg change from baseline (SD) | −0.28 (0.926) | −0.30 (0.892) | −0.43 (0.749) | −0.34 (0.372) |
| Intragroup *p*-value | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| Intergroup *p*-value | 0.782 | | 0.387 | |
| Mean HBsAg change from week 48 (SD) | 0.04 (0.585) | 0.03 (0.553) | −0.11 (0.454) | −0.08 (0.112) |
| Intragroup *p*-value | 0.118 | 0.367 | 0.001 | < 0.001 |
| Intergroup *p*-value | 0.816 | | 0.569 | |
| Percentage of patients with HBsAg decline ≥ 0.5 log (%) | 34.8% (151/434) | 35.3% (77/218) | 22.7% (39/172) | 20.0% (16/80) |
| Intergroup *p*-value | 0.875 | | 0.799 | |
| Percentage of patients with HBsAg decline ≥ 1.0 log (%) | 18.4% (80/434) | 13.3% (29/218) | 9.9% (17/172) | 8.8% (7/80) |
| Intergroup *p*-value | 0.104 | | 0.995 | |
| Data are *n*/N or *n*/*n* (%) unless otherwise stated. Patients without HBsAg results were not included. The highest level of multiple HBsAg results at the treatment beginning was adopted as the baseline value if the diversity was larger than 0.5 log10 IU/mL, otherwise, the latest one was adopted. P-value was calculated by ANCOVA for intergroup comparison and Wilcoxon signed-rank test for intragroup comparison. The difference of proportion was from the CMH test, the adjusted factors include HBV DNA level at baseline and the history of oral anti-HBV drug. HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen. | | | | |
|  |
|  |